Millipore Sigma Vibrant Logo

476275 Myricetin - CAS 529-44-2 - Calbiochem

A cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties.

Myricetin - CAS 529-44-2 - Calbiochem: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: 3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II

View Products on Sigmaaldrich.com
476275
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
529-44-2C₁₅H₁₀O₈

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
476275-25MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Kst.-Ampulle 25 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki = ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      Catalogue Number476275
      Brand Family Calbiochem®
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      References
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      Product Information
      CAS number529-44-2
      FormYellowish brown solid
      Hill FormulaC₁₅H₁₀O₈
      Chemical formulaC₁₅H₁₀O₈
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      476275-25MG 04055977184471

      Documentation

      Myricetin - CAS 529-44-2 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      Myricetin - CAS 529-44-2 - Calbiochem Analysenzertifikate

      TitelChargennummer
      476275

      Literatur

      Übersicht
      Lee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision21-November-2008 JSW
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      DescriptionA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      FormYellowish brown solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number529-44-2
      Chemical formulaC₁₅H₁₀O₈
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.